More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8%...


More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8% following FDA approval of Kadcyla. The drug is being approved with a Boxed Warning alerting users and prescribers of heart and liver toxicity as well as severe life-threatening birth defects.

From other sites
Comments (3)
  • wigit5
    , contributor
    Comments (4365) | Send Message
     
    This could cure you or it might kill you we aren't exactly sure... take two and see us in the morning.
    22 Feb 2013, 10:31 AM Reply Like
  • Obvious Troll
    , contributor
    Comments (6) | Send Message
     
    This drug is huge for the market, surprised there isn't more movement
    22 Feb 2013, 11:51 AM Reply Like
  • tomlewis727
    , contributor
    Comments (11) | Send Message
     
    Is this the reason why shares haven't skyrocketed after the announcement?
    22 Feb 2013, 11:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs